Patients receiving sitagliptin with metformin and glimepiride had significant improvements in A1C and FPG compared to patients receiving placebo with metformin and glimepiride (Table 11), with mean reductions from baseline relative to placebo in A1C of -0.9% and in FPG of -21 mg/dL
Kojima M, Hosoda H, Date Y, et al
Discover the incredible benefits that Semaglutide has to offer and learn how to kick start your journey to a healthier, happier you, full of self-confidence and vitality!
Nearly half (48.3%) of the cohort had obesity and 50.7% had type 2 diabetes
initiation of a drug or a new diagnosis) in an insulin-only arm, but this is an area of future study
Retatrutide has not received MHRA marketing authorisation and cannot be legally prescribed in the UK through NHS or private channels